Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?

TR Number
Date
2021-12-19
Journal Title
Journal ISSN
Volume Title
Publisher
Baishideng Publishing Group
Abstract

Antipsychotic agents are used for various indications in the treatment of psychiatric disorders. Despite their proven roles in multiple conditions, the treatment-emergent side effects of antipsychotic medications, such as metabolic side effects, are often the limiting factor for their long-term and short-term uses. Moreover, antipsychotic medications are often criticized for being less effective in treating different disabling symptoms such as negative symptoms of schizophrenia. As a result, the search for safer and more efficacious antipsychotic agents is ongoing. Newer antipsychotic agents are gaining attention related to emerging efficacy and tolerability data in treating neuropsychiatric conditions. In this review, we attempt to appraise the scientific data on psychopharmacology, safety profile, and efficacy of the newer additions to the list of second-generation antipsychotics, namely brexpiprazole, cariprazine, and lumateperone. We conducted a selective review utilizing PubMed, clinicaltrials.gov, and Cochrane databases to gather appropriate publications, keeping broad inclusion criteria. There were no restrictions on the age of the study population or the year of publication. We also cross-referenced articles and references to capture all existing studies. Our review of the current literature indicates that all three antipsychotic agents appear to be promising based on their short-term studies, while long-term studies remain limited. There is also a need for a head to head comparison between the newer antipsychotics with the other antipsychotic agents to ascertain if the newer agents are any better than the others.

Description
Keywords
Psychiatry, Antipsychotic agent, Brexpiprazole, Cariprazine, Lumateperone, Psychopharmacology, Schizophrenia, PREDOMINANT NEGATIVE SYMPTOMS, MAJOR DEPRESSIVE DISORDER, DOPAMINE D-3 RECEPTOR, DOUBLE-BLIND, ACUTE EXACERBATION, INADEQUATE RESPONSE, ACUTE SCHIZOPHRENIA, EFFICACY, SAFETY, PHASE-3, Antipsychotic agent, Brexpiprazole, Cariprazine, Lumateperone, Psychopharmacology, Schizophrenia
Citation